Data of Programmed death-ligand 1 expression and VEGF: Nivolumab Plus Bevacizumab, Paclitaxel For HER2-Negative Metastatic Breast Cancer (WJOG9917BTR)
收藏Mendeley Data2026-04-09 收录
下载链接：
https://data.mendeley.com/datasets/kfwz4s83zp
下载链接
链接失效反馈官方服务：
资源简介：
NEWBEAT was a phase 2, multicenter, single-arm trial that sought to evaluate the efficacy and safety of first-line triple therapy comprising nivolumab, bevacizumab, and paclitaxel in patients with HER2-negative advanced metastatic or inoperable recurrent BC. The purpose of the accompanying biomarker study (WJOG9917BTR) was to explore potential biomarkers of the efficacy and toxicity of triple therapy in patients with HER2-negative mBC.
提供机构：
Yukinori Ozaki
